regulatory
confidence high
sentiment negative
materiality 0.60
aTYR PHARMA INC (ATYR): Nasdaq/NYSE listing notice — aTyr Pharma receives Nasdaq bid-price deficiency notice; 180 days to cure
aTYR PHARMA INC
- On Dec 4, 2025, Nasdaq notified ATYR that its common stock closed below $1.00 for 30 consecutive business days.
- Company has until June 2, 2026 to regain compliance with Nasdaq Listing Rule 5550(a)(2).
- If not cured, may be eligible for a second 180-day period by meeting other initial listing standards.
- Company may consider a reverse stock split if needed to cure the deficiency.
- Failure to regain compliance could lead to delisting and an appeal process.